ArticleActa pharmaceutica Sinica. B2024
Macrophage P2Y
Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Purinergic signaling in osteoarthritis: Mechanistic insights into pathogenesis and therapeutic targeting.Genes & diseases · 2026Review
- RAS P21 Protein Activator 3 finetunes Type I immunity by limiting HCK-mediated STAT4 phosphorylation.Nature communications · 2026Article
- P2RY6Cellular oncology (Dordrecht, Netherlands) · 2026Article
- IL-27 signaling mediates skin inflammation in experimental psoriasis and atopic dermatitis.Cell & bioscience · 2026Article
- Role of dendritic cells and B cells in the skin of imiquimod (IMQ)-induced psoriasis-like mouse model.PeerJ · 2026Article
- IL-27Ra promotes the progression of neonatal necrotizing enterocolitis.Scientific reports · 2025Article
- P2Y6 promoted pruning of FSTL1 nerves by cutaneous macrophages to reset pain threshold and cardiac function.Purinergic signalling · 2025Article
- Decoding Macrophage Dynamics: A Pathway to Understanding and Treating Inflammatory Skin Diseases.International journal of molecular sciences · 2025Review
- Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression.Acta pharmaceutica Sinica. B · 2025Article
- Exploration of Targets Potentially Linked to IL-17A Inhibitor Response in Psoriasis Using Machine Learning.Clinical, cosmetic and investigational dermatology · 2025Article
- Transcriptional profiles of vaccine-induced protection in bovine herpesvirus-1 andFrontiers in veterinary science · 2025Article
- Skin Metabolic Signatures of Psoriasis and Psoriasis Concurrent with Metabolic Syndrome.Journal of inflammation research · 2025Article
- Nanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy.Pharmaceutics · 2024Review
- Functionalized Congeners of 2Cells · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purinergic signaling plays a causal role in the modulation of immune inflammatory response in the course of psoriasis, but its regulatory mechanism remains unclear. As a member of purinoceptors, P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.